Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.21.B10 extracted from

  • Spencer, B.; Valera, E.; Rockenstein, E.; Trejo-Morales, M.; Adame, A.; Masliah, E.
    A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy (2015), Mol. Neurodegener., 10, 48 .
    View publication on PubMedView publication on EuropePMC
Search for more literature for 3.4.21.B10

Cloned(Commentary)

Cloned (Comment) Organism
the enzyme is cloned into the third generation self-inactivating lentivirus vector with the CMV promoter driving expression Mus musculus

Protein Variants

Protein Variants Comment Organism
R80Q a neurosin genetically modified for increased half-life Mus musculus

Natural Substrates/ Products (Substrates)

Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
alpha-synuclein + H2O Mus musculus
-
 ?
-
 ?

Organism

Organism UniProt Comment Textmining
Mus musculus Q91Y82
-
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
alpha-synuclein + H2O
-
 Mus musculus ?
-
 ?

Synonyms

Synonyms Comment Organism
kallikrein-6
-
 Mus musculus

General Information

General Information Comment Organism
additional information brain-targeted neurosin accumulates throughout the CNS in neurons, astrocytes and microglia, and results in reduced accumulation of alpha-synuclein in oligodendrocytes and astrocytes with possible clearance via microglia. It also ameliorates myelin degeneration, neuropathology and behavioral deficits. The modified, brain-targeted neurosin may warrant further investigation as potential therapy for multiple system atrophy Mus musculus